Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Paly, Victoria Federico
18  Ergebnisse:
Personensuche X
?
1

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Tre..:

Baker, Timothy ; Johnson, Helen ; Kotapati, Srividya...
PharmacoEconomics - Open.  6 (2022)  5 - p. 697-710 , 2022
Link: https://doi.org/10.1007/..
 
?
2

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple..:

Paly, Victoria Federico ; Vallejo-Aparicio, Laura Amanda ; Martin, Alan...
International Journal of Chronic Obstructive Pulmonary Disease.  17 (2022)  - p. 3097-3109 , 2022
Link: https://doi.org/10.2147/..
 
?
3

Economic evaluation of nivolumab combined with ipilimumab i..:

Paly, Victoria Federico ; Hikichi, Yusuke ; Baker, Timothy...
Journal of Medical Economics.  23 (2020)  12 - p. 1542-1552 , 2020
Link: https://doi.org/10.1080/..
 
?
4

Long-term cost and utility consequences of short-term clini..:

Paly, Victoria Federico ; Naya, Ian ; Gunsoy, Necdet B...
International Journal of Chronic Obstructive Pulmonary Disease.  14 (2019)  - p. 939-951 , 2019
Link: https://doi.org/10.2147/..
 
?
5

Identifying the Benefits and Risks of Emerging Treatments f..:

Bridges, John F. P. ; Paly, Victoria Federico ; Barker, Elizabeth.
The Patient - Patient-Centered Outcomes Research.  8 (2014)  1 - p. 85-92 , 2014
Link: https://doi.org/10.1007/..
 
?
6

Hospital days, hospitalization costs, and inpatient mortali..:

Zilberberg, Marya D ; Shorr, Andrew F ; Huang, Huan...
BMC Infectious Diseases.  14 (2014)  1 - p. , 2014
Link: https://doi.org/10.1186/..
 
?
7

Heterogeneity in Survival with Immune Checkpoint Inhibitors..:

Federico Paly, Victoria ; Kurt, Murat ; Zhang, Lirong...
MDM Policy & Practice.  7 (2022)  1 - p. 238146832210896 , 2022
Link: https://doi.org/10.1177/..
 
?
8

Survival, healthcare resource use and costs among stage IV ..:

Lang, Kathleen ; Huang, Huan ; Sasane, Medha...
BMC Health Services Research.  14 (2014)  1 - p. , 2014
Link: https://doi.org/10.1186/..
 
?
9

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Tre..:

Baker, Timothy ; Johnson, Helen ; Kotapati, Srividya...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440167/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
10

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple..:

Paly, Victoria Federico ; Vallejo-Aparicio, Laura Amanda ; Martin, Alan...
info:eu-repo/semantics/altIdentifier/doi/10.2147/COPD.S366765.  , 2022
Link: https://www.dovepress.co..
 
?
11

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple..:

Paly, Victoria Federico ; Vallejo-Aparicio, Laura Amanda ; Martin, Alan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766529/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
12

Long-term cost and utility consequences of short-term clini..:

Paly, Victoria Federico ; Naya, Ian ; Gunsoy, Necdet B...
info:eu-repo/semantics/altIdentifier/doi/10.2147/COPD.S188898.  , 2019
Link: https://www.dovepress.co..
 
?
13

Long-term cost and utility consequences of short-term clini..:

Paly, Victoria Federico ; Naya, Ian ; Gunsoy, Necdet B...
https://researchonline.lshtm.ac.uk/id/eprint/4654576/1/Long-term%20cost%20and%20utility%20consequences%20of%20short-term%20clinically%20important%20deterioration%20in%20patients%20with%20chronic%20obstructiv.pdf.  , 2019
Link: https://researchonline.l..
 
?
14

Long-term cost and utility consequences of short-term clini..:

Paly, Victoria Federico ; Naya, Ian ; Gunsoy, Necdet B...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524132/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
15

Heterogeneity in Survival with Immune Checkpoint Inhibitors..:

Victoria Federico Paly ; Murat Kurt ; Lirong Zhang...
https://doi.org/10.1177/23814683221089659.  , 2022
Link: https://doi.org/10.1177/..
 
1-15